Autologous stem cell transplant (Auto-SCT) is increasingly used in older patients with
multiple myeloma (MM), despite lack of phase 3 trials in this age-defined population. For 207 …

The role of autologous stem cell transplantation (AuSCT) in older multiple myeloma patients
is unclear. Using data from the Autologous Blood and Marrow Transplant Registry, we …

Autologous stem cell transplantation (ASCT) is still debatable in treatment of patients over
65 years with multiple myeloma (MM). We performed a retrospective analysis of newly …

High‐dose therapy and autologous stem cell transplant (HDT) have been shown to prolong
survival in multiple myeloma (MM) in randomized trials, but only included patients of 65 …

Autologous stem cell transplantation (ASCT) has been used for treating multiple myeloma
(MM) for over three decades and is generally reserved for patients younger than 65. Herein …

We retrospectively analyzed the outcomes of all consecutive patients with myeloma (n= 84)
aged≥ 70 years who had received autologous hematopoietic stem cell transplant (auto …

Clinical trials evaluating the role of autologous hematopoietic stem cell transplantation (auto-
HCT) in multiple myeloma have mostly included patients aged< 65 years. Therefore, this …

Several clinical trials have shown the superiority of autologous stem cell transplantation over
conventional dose therapy for patients with multiple myeloma. This treatment, however, is …

Objective The feasibility and efficacy of high-dose melphalan (HD-MEL) followed by
autologous hematopoietic stem cell transplantation (auto-SCT) in elderly patients with …

The feasibility and efficacy of high-dose melphalan followed by autologous hematopoietic
stem cell transplantation in newly diagnosed elderly patients with multiple myeloma was …